Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
Express Scripts
Merck
Johnson and Johnson

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR RUCAPARIB CAMSYLATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rucaparib Camsylate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02740712 ↗ Pharmacokinetic Drug-Drug Interaction Study of Rucaparib Completed Clovis Oncology, Inc. Phase 1 2016-04-01 The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.
NCT03442556 ↗ Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Recruiting National Cancer Institute (NCI) Phase 2 2018-08-24 This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
NCT03442556 ↗ Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Recruiting University of Washington Phase 2 2018-08-24 This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rucaparib Camsylate

Condition Name

Condition Name for Rucaparib Camsylate
Intervention Trials
BRCA1 Gene Mutation 2
BRCA2 Gene Mutation 2
Castration-Resistant Prostate Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rucaparib Camsylate
Intervention Trials
Adenocarcinoma 2
Prostatic Neoplasms 2
Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rucaparib Camsylate

Trials by Country

Trials by Country for Rucaparib Camsylate
Location Trials
United States 46
Poland 3
Slovakia 1
Czechia 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rucaparib Camsylate
Location Trials
Ohio 3
Washington 3
New York 2
Iowa 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rucaparib Camsylate

Clinical Trial Phase

Clinical Trial Phase for Rucaparib Camsylate
Clinical Trial Phase Trials
Phase 3 1
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rucaparib Camsylate
Clinical Trial Phase Trials
Recruiting 3
Completed 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rucaparib Camsylate

Sponsor Name

Sponsor Name for Rucaparib Camsylate
Sponsor Trials
Clovis Oncology, Inc. 4
National Cancer Institute (NCI) 2
University of Washington 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rucaparib Camsylate
Sponsor Trials
Industry 5
Other 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.